Supportive and Palliative Care

Analysis of Peripherally Inserted Central Catheter Line in Cancer Patients: A Single-Center Experience

Sulav Sapkota¹  Raju Sannur¹  Radheshyam Naik¹

¹Department of Medical Oncology and Hematology, Healthcare Global Enterprises Limited, Bengaluru, Karnataka, India

South Asian J Cancer 2021;9:253–256.

Abstract

Background  Peripherally inserted central venous catheters are now widely used in cancer patients who require long-term treatment, for delivering multiple infusates. We aimed to evaluate the overall use of peripherally inserted central catheter (PICC) line in cancer patients, with the objective to study the demographic profile, complications, and safety related to PICC line in cancer patients.

Methods  All the patients undergoing treatment for hematological and solid malignancies with PICC line inserted at the Healthcare Global Hospital during the study were evaluated prospectively. The complications related to PICC and its safety were analyzed.

Results  Five hundred PICCs were inserted over a period of 2 years to 8 months for a total of 62,440 catheter days (mean of 24 days, i.e., 4.2 months, range: 1–434 days). The most common indication for PICC was for delivering chemotherapy (100%). Of these, 51 (10.2%) PICCs had complications at the rate of 0.82/1000 PICC days, and hence, 41 PICCs were removed. Hematological malignancies had more complications as compared with those with solid malignancies.

Conclusions  PICCs are comparatively safe method for the central venous access in cancer patients.

Introduction

Peripherally inserted central catheter (PICC) is one of the vascular access devices (VADs) that can be used for a prolonged period of time and is useful for chemotherapy infusions, antibiotic therapy, and blood transfusion as well as total parenteral nutrition. It is inserted in a peripheral vein in the cubital fossa, either the cephalic, basilic, or brachial vein and then advanced toward the heart, till the tip reaches the distal superior vena cava or cavoatrial junction. It was first described in 1975,¹ as an alternative to central venous catheters such as subclavian catheters, internal jugular, or femoral catheter, which have shown to have higher rate of infections.

Subclavian and jugular vein catheters might result in pneumothorax, while due to the method of placement, PICCs have shown to have comparatively lesser complications. The PICC catheter is either made up of silicon rubber or polyurethane, where silicon rubber has a lower risk of thrombosis.²

Indications, contraindications, and potential complications must be considered prior to the insertion of a PICC. With advancing age and increasing comorbidities in our modern society, adequate venous access can sometimes be very difficult to establish. PICCs provide reliable and safe intravenous access in a variety of indications.³ One advantage of PICCs is that, it can be used for any infusate, irrespective of pH, osmolality, or other chemical properties of the solution or medication. Many intravenous medications and solutions can cause damage to the peripheral venous endothelium and should be administered centrally to avoid this damage.⁴ Many
intra-middle venous endothelium and should be adminis-
tered centrally to avoid this damage.4 There is high blood flow
(≈2.1/min) around the central terminal tip of the PICC cath-
der that causes immediate dilution of the infusate, which
helps to protect the vessel wall from chemical irritation.

Although PICCs can remain in situ for extended periods of
time, ranging from 7 days to 1 year, there is no established
dwell time for PICCs,1,5 but if the therapy is expected to last
longer than 1 year, a more permanent type of central access
device should be considered, such as a tunneled catheter or
implanted port. However, PICCs offer certain advantages over
other forms of long-term VAD.6

We conducted this study to analyze the overall use of
PICCs in cancer patients attending our hospital.

**Study Design and Methods**

This prospective study was conducted over a period of
3 years and 6 months from June 2015 to December 2018
at our tertiary comprehensive cancer hospital. A 4-Fr
single-lumen triple-valved PICC was inserted under strict
aseptic conditions and ultrasonography guidance. The
PICCs were inserted in any of the major veins of the upper
extremity and secured by stat-lock adhesive dressing and
sutures. We prospectively studied and followed all patients
in the insertion period, who had a PICC successfully inserted
during the study, from June 15, 2015, to February 15, 2018,
that is, 2 years and 8 months and maintained a pro forma.
The last 10 months of the study period was dedicated for
the follow-up of these patients. Those patients with histo-
logically-proven hematological or solid malignancies were
included in the study, while those with bleeding and cloting
disorders were excluded. Weekly follow-up for these patients
was arranged with PICC team in the ward or minor operation
theater for the care of the VAD.

Written informed consent was obtained from all the
patients enrolled in the study. This study was approved by the
Institutional Review Board.

**Statistical Analysis**

The pro forma included the details of the patient and all the
parameters related to PICC line such as name, age, sex, diagno-
sis, patient status, date of insertion and removal of PICC, time
taken for insertion, length and depth of PICC line, number of
attempts for insertion, type of vein accessed, complication (if
any), and PICC dwell days. The data were analyzed using SPSS
software version 20. Demographic characteristics were sum-
marized by descriptive statistics. The rates of complications
were expressed by percentage and per 1,000 catheter days.
For the analysis, each PICC placement was counted as a new
event. In the case, where patients lost to follow-up, the final
visit was taken as the date of removal of PICC line.

**Observation and Results**

All the PICC lines were inserted by a trained person under
ultrasound guidance and strict aseptic condition in minor
operation theater. The mean number of attempts for skin
puncture was 1.2 (range: 1–4), and the mean duration of
time for PICC insertion from skin prick to fixation of PICC was
≈26.5 minutes (range: 6–120 minutes).

A total of 500 PICCs were inserted successfully during the
study. PICC was inserted thrice to two of the patients and
twice to ten patients. Five PICCs (1%) were lost to follow-up.
The demographic profile of patients and the details of PICC
placement are listed in ►Table 1. Overall, the patient popu-
lation included 245 (49%) men and 255 (51%) women, with
a mean age of 48 years (range: 7–83 years). Three hundred
and three patients (60.6%) had a solid malignancy and 197
(39.4%) had hematological malignancy. Among the solid
tumors, the most common were gastrointestinal tract malign-
nancies (33%), while lymphoma was the most common (42%)
in the hematological malignancies. The basilic vein was used
most frequently, 422 times (84.4%) for PICC placement. All
patients (100%) were discharged from hospital with a PICC
in situ.

All the 500 PICCs were in place for a total of 62,440 catheter
days (mean of 124 days, i.e., 4.2 months; range: 1–434 days).
The most common indication for PICC was chemotherapy
(100%). The most frequently used chemotherapy regimen was
adjuvant chemotherapy for gastrointestinal cancer in solid can-
cers and induction chemotherapy for lymphoma in hematol-
geological cancers. Majority of patients preferred PICC in this section.

A total of 51 (10.2%) complications, at the rate of 0.8/1000
catheter days, were observed during our study, out of which 17
(3.4%) infective complications (►Fig. 1) including both super-
ficial infection (phlebitis) and catheter-related bloodstream
infections (CRBSIs) were the most common complications,
while 3% was due to thrombotic event. We observed that out
of the 500 PICCS removed, 22 PICCs (4%) were removed due
to death of the patients caused by progression of the disease.
PICCs in 41 (8%) patients were removed due to complications
and 431 (86.2%) PICCs were removed at the completion of
therapy without any evidence of complications. We noticed
that those patients with PICCs with hematological malignan-
cies (11.6%) were found to have more complications than solid
malignancies (9.2%). We did not observe any death due to the
complications caused by PICC line.

**Discussion**

PICC is now emerging as one of the safe and efficacious
methods of VADs. Although it has been used increasingly in
majority of the cancer centers for the administration of che-
motherapy drugs in India, still, the review of literature in the
present work shows limited number of published articles.
Hence, our attempt in this prospective study is to share our
institutional experience with PICC line.

In the current study, patients were in between 7 and
84 years of age, with a mean of 48 years. Our comprehensive
tertiary cancer center is well equipped with the facilities to
deal with almost every cancer; hence, we observed a wider
range of the age of the patients in our study. This was in con-
trast to the findings of Haider et al.,7 where the patient age
group was between 14 and 40 years. In the present study,
Analysis of PICC Line in Cancer Patients

Sapkota et al.

South Asian Journal of Cancer Vol. 9 No. 4/2021 © 2020 MedInt Services Pvt Ltd.

PICC was mainly used for delivering chemotherapy to cancer patients. We observed overall 10.2% complications in our patients, where mainly 3.4% was due to infective causes (CRBSI and phlebitis combined), while 3% was due to thrombosis. The possible explanation of infection-related complications in our setting is because of the multiple use of PICC line, use of steroids, and immunocompromised state of the patients renders them for infection. The hospital-acquired infections are another threat for developing the infective complications in these patients.

Of the 500 PICCs inserted in the present study, we observed that 431 (86.2%) completed the respective therapies without any complications; while out of the 10.2% patients who developed complications, 8% PICCs were removed. The remaining 2.2% patients were salvaged with regular dressing and oral antibiotic, especially in cases of phlebitis. We did not observe any death due to PICC line complications, although 4% of the patients who died were because of the progression of the disease.

Table 1 Characteristics of the patients receiving a peripherally inserted central catheter (n = 500)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Number of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic profile</td>
<td></td>
</tr>
<tr>
<td>Age (mean in year)</td>
<td>48</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>245 (49)</td>
</tr>
<tr>
<td>Female</td>
<td>255 (51)</td>
</tr>
<tr>
<td>Categorization of cancer</td>
<td></td>
</tr>
<tr>
<td>Overall solid tumors</td>
<td>303 (60.6)</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>85 (17)</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>103 (20.6)</td>
</tr>
<tr>
<td>Head and neck</td>
<td>41 (8.2)</td>
</tr>
<tr>
<td>Gynecological</td>
<td>31 (6.2)</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>16 (3.2)</td>
</tr>
<tr>
<td>Others</td>
<td>27 (5.4)</td>
</tr>
<tr>
<td>Overall hematological cancer</td>
<td>197 (39.4)</td>
</tr>
<tr>
<td>AML</td>
<td>50 (10)</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>84 (16.8)</td>
</tr>
<tr>
<td>ALL</td>
<td>30 (6.4)</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>17 (3.4)</td>
</tr>
<tr>
<td>Others</td>
<td>16 (3.2)</td>
</tr>
<tr>
<td>Site of PICC line insertion</td>
<td></td>
</tr>
<tr>
<td>Right basilic vein</td>
<td>87 (16.7)</td>
</tr>
<tr>
<td>Left basilic vein</td>
<td>335 (67)</td>
</tr>
<tr>
<td>Right cephalic vein</td>
<td>5 (0.2)</td>
</tr>
<tr>
<td>Left cephalic vein</td>
<td>31 (6.2)</td>
</tr>
<tr>
<td>Right brachial vein</td>
<td>19 (3.8)</td>
</tr>
<tr>
<td>Left brachial vein</td>
<td>23 (4.6)</td>
</tr>
<tr>
<td>Overall complications</td>
<td>51 (10.2)</td>
</tr>
<tr>
<td>CRBSI</td>
<td>8 (1.6)</td>
</tr>
<tr>
<td>Phlebitis</td>
<td>9 (1.8)</td>
</tr>
<tr>
<td>Blockage</td>
<td>6 (1.2)</td>
</tr>
<tr>
<td>Accidental removal</td>
<td>3 (0.6)</td>
</tr>
<tr>
<td>Leakage</td>
<td>5 (1.0)</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>15 (3.0)</td>
</tr>
<tr>
<td>Abnormal position</td>
<td>4 (0.8)</td>
</tr>
<tr>
<td>Hematoma</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Total PICCs removed</td>
<td></td>
</tr>
<tr>
<td>Removal due to death</td>
<td>22 (4.4)</td>
</tr>
<tr>
<td>Removal due to complications</td>
<td>42 (8.4)</td>
</tr>
<tr>
<td>Removal after completion of treatment without complications</td>
<td>431 (86.2)</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>5 (1.0)</td>
</tr>
</tbody>
</table>

Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CRBSI, catheter-related bloodstream infections; GIT, gastrointestinal tract; PB, pancreato-biliary; PICCs, peripherally inserted central catheters.
The major challenge that we faced in our work was the VAD care to prevent complications. To deal with the issue, we arranged a regular follow-up for VAD care with our PICC-trained nurses, at each scheduled chemotherapy dates of the patients. We had also educated the patient attendants as well as local healthcare providers for basic VAD care and dressing. These measures increased the patient compliance with PICC line.

The considerable number of patients enrolled in the present study forms its strength as not many publications from developing nations such as India are available for the use of PICC line in cancer patients. As we did not observe any deaths related to PICC or its complications, we suggest it to be safer methods for central venous access. The shortcoming of our work is inability to study the quality of life, social impact, and financial issues related to PICC line in cancer patients.

Conclusions

Our study reinforces the notion that PICC line is safe, convenient, and is a safer mode of the central venous access in cancer patients even in Indian population. It can be used without much complication for a longer duration of time in patients needing chemotherapy. However, the quality of life, financial issues of the patients with PICC line still need to be addressed, for which more prospective studies are recommended.

Funding

None.

Conflicts of Interest

There are no conflicts of interest.

References


Certificate Course in Telemedicine Practice Guidelines

If you want to get certified in doing Telemedicine Consultation (as per requirements of Govt of India notification), please enrol for the six module online course at:
https://www.onference.in/c/certificate-course-in-telemedicine-by-acdh/1610
for further details please email mediclawgic@gmail.com